MVCD2
MCID: MCR112
MIFTS: 41

Microvascular Complications of Diabetes 2 (MVCD2)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 2

MalaCards integrated aliases for Microvascular Complications of Diabetes 2:

Name: Microvascular Complications of Diabetes 2 56 73 29 13 6 39
Proliferative Diabetic Retinopathy 73 71
Diabetic Nephropathy 73 71
Mvcd2 56 73
Microvascular Complications of Diabetes, Susceptibility to, 2 56
Proliferative Retinopathy, Diabetic, Susceptibility to 56
End-Stage Renal Disease, Diabetic, Susceptibility to 56
Proliferative Retinopathy, Diabetic 56
End-Stage Renal Disease, Diabetic 56
Diabetic End-Stage Renal Disease 73

Classifications:



External Ids:

OMIM 56 612623
OMIM Phenotypic Series 56 PS603933
MeSH 43 D048909
UMLS 71 C0011881 C0154830

Summaries for Microvascular Complications of Diabetes 2

UniProtKB/Swiss-Prot : 73 Microvascular complications of diabetes 2: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 2, also known as proliferative diabetic retinopathy, is related to microvascular complications of diabetes 3 and microvascular complications of diabetes 5. An important gene associated with Microvascular Complications of Diabetes 2 is EPO (Erythropoietin). The drugs Methylcobalamin and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include endothelial, eye and kidney.

More information from OMIM: 612623 PS603933

Related Diseases for Microvascular Complications of Diabetes 2

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 496, show less)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 3 12.3
2 microvascular complications of diabetes 5 12.1
3 background diabetic retinopathy 12.1
4 vitreoretinopathy, neovascular inflammatory 11.9
5 severe nonproliferative diabetic retinopathy 11.9
6 microvascular complications of diabetes 7 11.8
7 microvascular complications of diabetes 1 11.7
8 retinal detachment 11.1
9 macular retinal edema 10.9
10 renal fibrosis 10.9
11 macular holes 10.9
12 neovascular glaucoma 10.8
13 yemenite deaf-blind hypopigmentation syndrome 10.8
14 diabetic macular edema 10.8
15 vitreoretinopathy 10.7
16 glomerulonephritis 10.7
17 nephrotic syndrome 10.6
18 rubeosis iridis 10.6
19 end stage renal disease 10.6
20 retinal ischemia 10.6
21 eye disease 10.6
22 intraocular pressure quantitative trait locus 10.5
23 retinal disease 10.5
24 uremia 10.5
25 hypertension, essential 10.5
26 iga glomerulonephritis 10.5
27 hyperglycemia 10.5
28 vitreous detachment 10.5
29 membranous nephropathy 10.4
30 endophthalmitis 10.4
31 uveitis 10.4
32 glomerular disease 10.4
33 neuroretinitis 10.4
34 retinal vascular disease 10.4
35 retinitis 10.4
36 diabetes mellitus 10.4
37 kidney hypertrophy 10.4
38 preretinal fibrosis 10.4
39 hyperinsulinism 10.4
40 nephrosclerosis 10.4
41 hyperuricemia 10.3
42 diabetes mellitus, type i 10.3
43 atherosclerosis susceptibility 10.3
44 diabetes mellitus, noninsulin-dependent 10.3
45 retinitis pigmentosa 10.3
46 insulin-like growth factor i 10.3
47 retinoschisis 1, x-linked, juvenile 10.3
48 48,xyyy 10.3
49 rapidly involuting congenital hemangioma 10.3
50 proteasome-associated autoinflammatory syndrome 1 10.3
51 hypertriglyceridemia, familial 10.3
52 muscle hypertrophy 10.3
53 glucose intolerance 10.3
54 congestive heart failure 10.3
55 retinal vein occlusion 10.3
56 neuropathy 10.3
57 ocular hypertension 10.3
58 wilms tumor 5 10.3
59 focal segmental glomerulosclerosis 10.3
60 membranoproliferative glomerulonephritis 10.3
61 systemic lupus erythematosus 10.2
62 b-cell lymphoma 10.2
63 arteries, anomalies of 10.2
64 3-methylglutaconic aciduria, type iii 10.2
65 blind hypotensive eye 10.2
66 vascular disease 10.2
67 keratopathy 10.2
68 lipid metabolism disorder 10.2
69 ischemia 10.2
70 kidney disease 10.2
71 microvascular complications of diabetes 4 10.2
72 microvascular complications of diabetes 6 10.2
73 creatinine clearance quantitative trait locus 10.2
74 cardiovascular system disease 10.2
75 fatty liver disease 10.2
76 autoimmune disease 10.2
77 wilms tumor 1 10.2
78 body mass index quantitative trait locus 1 10.2
79 hypertensive nephropathy 10.2
80 interstitial nephritis 10.2
81 heart disease 10.2
82 proliferative glomerulonephritis 10.2
83 arteriolosclerosis 10.2
84 homocysteinemia 10.2
85 corneal edema 10.2
86 autonomic neuropathy 10.2
87 cerebrovascular disease 10.2
88 iridocyclitis 10.2
89 senile cataract 10.2
90 eales disease 10.2
91 hypoxia 10.2
92 pyelonephritis 10.1
93 thrombotic microangiopathy 10.1
94 acute cystitis 10.1
95 purpura 10.1
96 amyloidosis 10.1
97 fibrosis of extraocular muscles, congenital, 1 10.1
98 hypercholesterolemia, familial, 1 10.1
99 sarcoidosis 1 10.1
100 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
101 coronary heart disease 1 10.1
102 hyperlipoproteinemia, type iii 10.1
103 joint laxity, short stature, and myopia 10.1
104 neuropathy, congenital hypomyelinating, 2 10.1
105 lipoprotein quantitative trait locus 10.1
106 peripheral artery disease 10.1
107 rickets 10.1
108 retinal microaneurysm 10.1
109 hypertensive retinopathy 10.1
110 diabetic angiopathy 10.1
111 myopia 10.1
112 carotid stenosis 10.1
113 acromegaly 10.1
114 acute kidney failure 10.1
115 carotid artery disease 10.1
116 peripheral nervous system disease 10.1
117 chronic kidney disease 10.1
118 hypoglycemia 10.1
119 47,xyy 10.1
120 cerebrofacial arteriovenous metameric syndrome 10.1
121 iga nephropathy 1 10.1
122 ocular motor apraxia 10.1
123 body mass index quantitative trait locus 11 10.1
124 nephrotic syndrome, type 2 10.1
125 metabolic acidosis 10.1
126 polycystic kidney disease 10.1
127 gastroparesis 10.1
128 secondary hyperparathyroidism 10.1
129 gout 10.1
130 hyperparathyroidism 10.1
131 lactic acidosis 10.1
132 rapidly progressive glomerulonephritis 10.1
133 peritonitis 10.1
134 stroke, ischemic 10.0
135 body mass index quantitative trait locus 9 10.0
136 body mass index quantitative trait locus 8 10.0
137 body mass index quantitative trait locus 4 10.0
138 body mass index quantitative trait locus 10 10.0
139 body mass index quantitative trait locus 7 10.0
140 myocardial infarction 10.0
141 body mass index quantitative trait locus 12 10.0
142 body mass index quantitative trait locus 14 10.0
143 fatty liver disease, nonalcoholic 1 10.0
144 body mass index quantitative trait locus 18 10.0
145 body mass index quantitative trait locus 19 10.0
146 body mass index quantitative trait locus 20 10.0
147 sleep apnea 10.0
148 non-alcoholic fatty liver disease 10.0
149 renal hypertension 10.0
150 hemosiderosis 10.0
151 diabetic polyneuropathy 10.0
152 crescentic glomerulonephritis 10.0
153 beriberi 10.0
154 plasmacytoma 10.0
155 mesangial proliferative glomerulonephritis 10.0
156 liver cirrhosis 10.0
157 hypoaldosteronism 10.0
158 rare hereditary hemochromatosis 10.0
159 renal cell carcinoma, nonpapillary 10.0
160 systemic lupus erythematosus 13 10.0
161 epidural abscess 10.0
162 candidiasis 10.0
163 polyhydramnios 10.0
164 tubulocystic renal cell carcinoma 10.0
165 rare renal tumor 10.0
166 atrial standstill 1 10.0
167 osteoporosis 10.0
168 thrombophilia due to thrombin defect 10.0
169 coloboma, ocular, autosomal recessive 10.0
170 nephrotic syndrome, type 1 10.0
171 diamond-blackfan anemia 2 10.0
172 bone mineral density quantitative trait locus 8 10.0
173 diabetes mellitus, ketosis-prone 10.0
174 bone mineral density quantitative trait locus 15 10.0
175 hemorrhage, intracerebral 10.0
176 leukemia, acute lymphoblastic 3 10.0
177 hyperphosphatemia 10.0
178 thrombosis 10.0
179 chronic pyelonephritis 10.0
180 tuberous sclerosis 10.0
181 renovascular hypertension 10.0
182 liver disease 10.0
183 pustulosis of palm and sole 10.0
184 placenta disease 10.0
185 lupus erythematosus 10.0
186 psoriasis 10.0
187 anca-associated vasculitis 10.0
188 alzheimer disease 9.9
189 transient bullous dermolysis of the newborn 9.9
190 exudative vitreoretinopathy 1 9.9
191 glaucoma, primary open angle 9.9
192 keratitis, hereditary 9.9
193 macular dystrophy, dominant cystoid 9.9
194 renal failure, progressive, with hypertension 9.9
195 porphyria cutanea tarda 9.9
196 variegate porphyria 9.9
197 prader-willi syndrome 9.9
198 corneal dystrophy, band-shaped 9.9
199 hemochromatosis, type 1 9.9
200 immune deficiency disease 9.9
201 polycythemia vera 9.9
202 pseudoxanthoma elasticum 9.9
203 retinoschisis of fovea 9.9
204 wilson disease 9.9
205 coats disease 9.9
206 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 9.9
207 retinitis pigmentosa 11 9.9
208 branchiootic syndrome 1 9.9
209 macular degeneration, age-related, 1 9.9
210 maturity-onset diabetes of the young 9.9
211 angioid streaks 9.9
212 leukemia, chronic myeloid 9.9
213 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
214 transferrin serum level quantitative trait locus 2 9.9
215 robinow syndrome, autosomal dominant 2 9.9
216 visual impairment and progressive phthisis bulbi 9.9
217 peripheral vascular disease 9.9
218 angina pectoris 9.9
219 deficiency anemia 9.9
220 limb ischemia 9.9
221 cytomegalovirus retinitis 9.9
222 pre-eclampsia 9.9
223 open-angle glaucoma 9.9
224 gestational diabetes 9.9
225 allergic hypersensitivity disease 9.9
226 anisometropia 9.9
227 von willebrand's disease 9.9
228 posterior uveitis 9.9
229 leukostasis 9.9
230 branch retinal artery occlusion 9.9
231 central retinal artery occlusion 9.9
232 scleritis 9.9
233 eclampsia 9.9
234 panophthalmitis 9.9
235 polyneuropathy 9.9
236 hypothyroidism 9.9
237 urticaria 9.9
238 thrombocytopenia 9.9
239 vascular cancer 9.9
240 optic nerve disease 9.9
241 arteriosclerosis 9.9
242 hemoglobinopathy 9.9
243 arteriosclerosis obliterans 9.9
244 thyroiditis 9.9
245 diverticulitis 9.9
246 cataract 9.9
247 osteoarthritis 9.9
248 polycythemia 9.9
249 corneal ulcer 9.9
250 retinal degeneration 9.9
251 retinal artery occlusion 9.9
252 night blindness 9.9
253 vasculitis 9.9
254 eating disorder 9.9
255 myeloid leukemia 9.9
256 scotoma 9.9
257 diabetic neuropathy 9.9
258 refractive error 9.9
259 miliary tuberculosis 9.9
260 mitochondrial disorders 9.9
261 cytokine deficiency 9.9
262 heparin-induced thrombocytopenia 9.9
263 aneurysm 9.9
264 autonomic dysfunction 9.9
265 posttransplant acute limbic encephalitis 9.9
266 neurotrophic keratopathy 9.9
267 leukemia, acute monocytic 9.9
268 triiodothyronine receptor auxiliary protein 9.9
269 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.9
270 cystic fibrosis 9.9
271 wolfram syndrome 1 9.9
272 arts syndrome 9.9
273 aging 9.9
274 diabetes and deafness, maternally inherited 9.9
275 helicobacter pylori infection 9.9
276 huntington disease-like 3 9.9
277 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 9.9
278 abdominal obesity-metabolic syndrome 1 9.9
279 alveolar soft part sarcoma 9.9
280 huntington disease-like 2 9.9
281 mammary-digital-nail syndrome 9.9
282 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.9
283 pulmonary hypertension 9.9
284 sexual disorder 9.9
285 atrial fibrillation 9.9
286 obstructive nephropathy 9.9
287 bone disease 9.9
288 pertussis 9.9
289 disseminated intravascular coagulation 9.9
290 pulmonary edema 9.9
291 severe pre-eclampsia 9.9
292 acute poststreptococcal glomerulonephritis 9.9
293 bacteriuria 9.9
294 constipation 9.9
295 iron metabolism disease 9.9
296 familial nephrotic syndrome 9.9
297 bilirubin metabolic disorder 9.9
298 cryoglobulinemia 9.9
299 pulmonary fibrosis 9.9
300 immune-complex glomerulonephritis 9.9
301 monocytic leukemia 9.9
302 fasciitis 9.9
303 necrotizing fasciitis 9.9
304 acute monoblastic leukemia 9.9
305 dwarfism 9.9
306 familial hypertension 9.9
307 light chain deposition disease 9.9
308 mthfr gene variant 9.9
309 pure autonomic failure 9.9
310 encephalopathy 9.9
311 argyria 9.9
312 acute liver failure 9.9
313 heavy chain deposition disease 9.9
314 alcohol dependence 9.7
315 apnea, obstructive sleep 9.7
316 breast cancer 9.7
317 colorectal cancer 9.7
318 cardiac arrhythmia 9.7
319 maturity-onset diabetes of the young, type 1 9.7
320 maturity-onset diabetes of the young, type 2 9.7
321 gilbert syndrome 9.7
322 antigen defined by monoclonal antibody t87 9.7
323 optic atrophy 1 9.7
324 polykaryocytosis inducer 9.7
325 pulmonary fibrosis, idiopathic 9.7
326 retinoblastoma 9.7
327 polycystic ovary syndrome 1 9.7
328 tuberous sclerosis 1 9.7
329 urate oxidase, pseudogene 9.7
330 volvulus of midgut 9.7
331 lung cancer 9.7
332 apparent mineralocorticoid excess 9.7
333 fanconi-bickel syndrome 9.7
334 hutterite cerebroosteonephrodysplasia syndrome 9.7
335 acetylation, slow 9.7
336 spondylometaphyseal dysplasia, sedaghatian type 9.7
337 myeloma, multiple 9.7
338 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 9.7
339 gitelman syndrome 9.7
340 thymoma, familial 9.7
341 vascular hyalinosis 9.7
342 ataxia and polyneuropathy, adult-onset 9.7
343 maturity-onset diabetes of the young, type 3 9.7
344 budd-chiari syndrome 9.7
345 diabetes mellitus, insulin-dependent, 15 9.7
346 acute insulin response 9.7
347 diabetes mellitus, noninsulin-dependent, 3 9.7
348 paragangliomas 3 9.7
349 pseudohyperkalemia, familial, 2, due to red cell leak 9.7
350 hepatitis c virus 9.7
351 lung cancer susceptibility 3 9.7
352 diabetes mellitus, insulin-dependent, 23 9.7
353 pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis 9.7
354 tuberous sclerosis 2 9.7
355 plasminogen activator inhibitor-1 deficiency 9.7
356 beta-thalassemia 9.7
357 graft-versus-host disease 9.7
358 epileptic encephalopathy, childhood-onset 9.7
359 hyperprolactinemia 9.7
360 pachyonychia congenita 3 9.7
361 nephrotic syndrome, type 10 9.7
362 analbuminemia 9.7
363 autoimmune lymphoproliferative syndrome, type v 9.7
364 chorea, childhood-onset, with psychomotor retardation 9.7
365 hydrops, lactic acidosis, and sideroblastic anemia 9.7
366 hypertrophic scars 9.7
367 chlamydia pneumonia 9.7
368 autoimmune glomerulonephritis 9.7
369 mineral metabolism disease 9.7
370 arrhythmogenic right ventricular cardiomyopathy 9.7
371 exanthem 9.7
372 extrapulmonary tuberculosis 9.7
373 vitamin b12 deficiency 9.7
374 anaplastic large cell lymphoma 9.7
375 heavy chain disease 9.7
376 gamma heavy chain disease 9.7
377 alexithymia 9.7
378 colitis 9.7
379 autoimmune neuropathy 9.7
380 drug allergy 9.7
381 bone resorption disease 9.7
382 myoglobinuria 9.7
383 type 1 diabetes mellitus 17 9.7
384 angioimmunoblastic t-cell lymphoma 9.7
385 trypanosomiasis 9.7
386 osteomyelitis 9.7
387 aortic atherosclerosis 9.7
388 thalassemia 9.7
389 malignant hypertension 9.7
390 lipoid nephrosis 9.7
391 henoch-schoenlein purpura 9.7
392 microcytic anemia 9.7
393 chlamydia 9.7
394 megacolon 9.7
395 corneal neovascularization 9.7
396 diabetic autonomic neuropathy 9.7
397 polycystic ovary syndrome 9.7
398 hepatic coma 9.7
399 acute kidney tubular necrosis 9.7
400 telangiectasis 9.7
401 choreatic disease 9.7
402 dilated cardiomyopathy 9.7
403 exocrine pancreatic insufficiency 9.7
404 diabetic cataract 9.7
405 pure red-cell aplasia 9.7
406 interstitial cystitis 9.7
407 toxic shock syndrome 9.7
408 angioedema 9.7
409 cystitis 9.7
410 squamous cell carcinoma 9.7
411 pericarditis 9.7
412 impotence 9.7
413 hepatitis c 9.7
414 malignant fibrous histiocytoma 9.7
415 hypogonadism 9.7
416 enthesopathy 9.7
417 ectodermal dysplasia 9.7
418 dental caries 9.7
419 wernicke encephalopathy 9.7
420 agammaglobulinemia 9.7
421 tic disorder 9.7
422 pulmonary tuberculosis 9.7
423 antiphospholipid syndrome 9.7
424 gastric dilatation 9.7
425 thymoma 9.7
426 histiocytosis 9.7
427 cellulitis 9.7
428 cerebral arterial disease 9.7
429 intermittent claudication 9.7
430 arthropathy 9.7
431 insulinoma 9.7
432 hepatic tuberculosis 9.7
433 myopathy 9.7
434 coronary stenosis 9.7
435 fibrous histiocytoma 9.7
436 familial retinoblastoma 9.7
437 uremic neuropathy 9.7
438 calciphylaxis 9.7
439 exudative glomerulonephritis 9.7
440 elephantiasis 9.7
441 nutritional deficiency disease 9.7
442 urinary tract obstruction 9.7
443 sleep disorder 9.7
444 pneumonia 9.7
445 connective tissue disease 9.7
446 mitochondrial metabolism disease 9.7
447 monoclonal gammopathy of uncertain significance 9.7
448 muscular atrophy 9.7
449 myocarditis 9.7
450 periodontitis 9.7
451 intestinal obstruction 9.7
452 ileus 9.7
453 pyridoxine deficiency anemia 9.7
454 mucormycosis 9.7
455 ulcerative colitis 9.7
456 pyomyositis 9.7
457 amebiasis 9.7
458 homocystinuria 9.7
459 hypopituitarism 9.7
460 pulmonary embolism 9.7
461 pathologic nystagmus 9.7
462 hypervitaminosis d 9.7
463 hypereosinophilic syndrome 9.7
464 berardinelli-seip congenital lipodystrophy 9.7
465 aminoaciduria 9.7
466 brittle diabetes 9.7
467 c1q nephropathy 9.7
468 chronic thromboembolic pulmonary hypertension 9.7
469 crystal arthropathies 9.7
470 diffuse mesangial sclerosis 9.7
471 fibrillary glomerulonephritis 9.7
472 granulocytopenia 9.7
473 immunotactoid glomerulopathy 9.7
474 monogenic diabetes 9.7
475 mycobacterium marinum 9.7
476 reversible cerebral vasoconstriction syndrome 9.7
477 stevens-johnson syndrome/toxic epidermal necrolysis 9.7
478 brain injury 9.7
479 cerebral beriberi 9.7
480 dysphagia 9.7
481 headache 9.7
482 syncope 9.7
483 traumatic brain injury 9.7
484 t-cell non-hodgkin lymphoma 9.7
485 chronic acquired demyelinating polyneuropathy 9.7
486 idiopathic nephrotic syndrome 9.7
487 arterial thoracic outlet syndrome 9.7
488 acute generalized exanthematous pustulosis 9.7
489 benign idiopathic neonatal seizures 9.7
490 pik3ca-related overgrowth syndrome 9.7
491 premature aging 9.7
492 collagen type iii glomerulopathy 9.7
493 polyploidy 9.7
494 light and heavy chain deposition disease 9.7
495 red cell aplasia 9.7
496 polyendocrinopathy 9.7

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 2:



Diseases related to Microvascular Complications of Diabetes 2

Symptoms & Phenotypes for Microvascular Complications of Diabetes 2

Clinical features from OMIM:

612623

Drugs & Therapeutics for Microvascular Complications of Diabetes 2

Drugs for Microvascular Complications of Diabetes 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 402, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
4
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
5
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
6
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
7
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
8
Methyldopa Approved Phase 4 555-30-6 38853
9
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
10
Capsaicin Approved Phase 4 404-86-4 1548943
11
Bevacizumab Approved, Investigational Phase 4 216974-75-3
12
Dipivefrin Approved Phase 4 52365-63-6 3105
13
Ranibizumab Approved Phase 4 347396-82-1 459903
14
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
15
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
16
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
17
Povidone-iodine Approved Phase 4 25655-41-8
18
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
19
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
20
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
21
Probucol Approved, Investigational Phase 4 23288-49-5 4912
22
Ramipril Approved Phase 4 87333-19-5 5362129
23
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
24
Doxazosin Approved Phase 4 74191-85-8 3157
25
Atorvastatin Approved Phase 4 134523-00-5 60823
26
Indapamide Approved Phase 4 26807-65-8 3702
27
Nisoldipine Approved Phase 4 63675-72-9 4499
28
Trandolapril Approved Phase 4 87679-37-6 5484727
29
Amlodipine Approved Phase 4 88150-42-9 2162
30
Verapamil Approved Phase 4 52-53-9 2520
31
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
32
Insulin glulisine Approved Phase 4 207748-29-6
33
Insulin glargine Approved Phase 4 160337-95-1
34
Liraglutide Approved Phase 4 204656-20-2 44147092
35
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
36
Nitric Oxide Approved Phase 4 10102-43-9 145068
37
Allopurinol Approved Phase 4 315-30-0 2094
38
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
39
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
40
Insulin lispro Approved Phase 4 133107-64-9
41
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
42
Clonidine Approved Phase 4 4205-90-7 2803
43
Atenolol Approved Phase 4 29122-68-7 2249
44
Glimepiride Approved Phase 4 93479-97-1 3476
45
Hydralazine Approved Phase 4 86-54-4 3637
46
Terazosin Approved Phase 4 63590-64-7 5401
47
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
48
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
49
Febuxostat Approved Phase 4 144060-53-7 134018
50
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
51
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
52
Canagliflozin Approved Phase 4 842133-18-0
53
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
54
Gliclazide Approved Phase 4 21187-98-4 3475
55
Adenosine Approved, Investigational Phase 4 58-61-7 60961
56
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
57
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
58
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
59
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
60
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
61
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
62
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4